Knight Therapeutics Inc., a specialty pharmaceutical company, has announced that its New Drug Submission (NDS) for CREXONT®, an extended-release oral formulation of carbidopa/levodopa capsules for Parkinson's disease treatment, has been accepted for review by Health Canada. The acceptance marks a significant step for Knight in its mission to expand its central nervous system portfolio and address the unmet medical needs of Parkinson's disease patients. This development follows Knight's agreement with Amneal Pharmaceuticals for exclusive rights to seek regulatory approval and commercialize CREXONT® in Canada and Latin America. Knight plans to submit marketing authorization applications in Mexico and Brazil later in 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.